Primary regulatory
Egrifta (tesamorelin): FDA Drug Label
FDA-approved drug label for Egrifta (tesamorelin for injection), indicated for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. The only GHRH/GHS-class peptide with FDA approval.
U.S. Food and Drug AdministrationPublished 2010-06-18Accessed 2026-07-01
Registry record
Source metadata
- Publisher
- U.S. Food and Drug Administration
- Source type
- Primary regulatory
- Registry ID
fda-egrifta-label
Source usage
Linked from 9 pages
Compound
Tesamorelin
ComparisonCJC-1295 + Ipamorelin vs Tesamorelin
ComparisonSermorelin vs Tesamorelin
Evidence curationBest Peptides for Growth Hormone Release
GuidePeptide Category Explainers: How Every Compound Class on This Site Is Defined
GuidePeptide Half-Life Reference Table
GuidePeptide Storage Guide: Lyophilized, Reconstituted, and Degradation
GuidePeptide Terminology Glossary
Research hubCompounded Peptides Explained: 503A vs 503B
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.